Companies › Marzieh Ebrahimi
2 active drug programs in 2 registered trials: 1 Phase 1, 1 Phase 2; Oncology; next expected readout Nov 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Active NK cell injection Natural killer cell-based immunotherapy | – | Phase 2 | Glioma Glioblastoma Multiforme | Nov 2027 |
| Allogenic NK cells Natural Killer cells extracted from healthy donor, processed and infused to enhance anti-t | – | Phase 1 | Neuroblastoma, Recurrent, Refractory | Nov 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06674265 | Allogenic NK cells | Phase 1 | Neuroblastoma, Recurrent, Refractory | Oncology | Nov 2026 |
| NCT06687681 | Active NK cell injection | Phase 2 | Glioma Glioblastoma Multiforme | Oncology | Nov 2027 |
No annotated target.
–
Hrain Biotechnology Beijing Yongtai Ruike Biotechnology Company Hebei Senlang Biotechnology Hangzhou Converd Abscint NV/SA
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.